Novartis, Teijin Pharma ink pact for preclinical candidate for proteinuric kidney diseases
Teijin Pharma will receive an upfront cash payment of USD 30 million from Novartis and is eligible to receive potential development and commercial milestone payments of up to USD 200 million.
Tokyo: Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, has announced that it has entered into an exclusive global license agreement with Novartis to research, develop, manufacture and commercialize an investigational preclinical candidate for proteinuric kidney diseases.
The investigational small molecule candidate was discovered at the Teijin Institute for Bio-medical Research, Teijin Pharma’s drug development base in Tokyo. The candidate acts in a genetically validated pathway and is believed to impact the pathogenesis of multiple kidney diseases.
Read also: EMA seeks to issue guidance on liver damage from Novartis gene therapy Zolgensma
Under the terms of the license agreement, Teijin Pharma will grant Novartis exclusive worldwide rights to research, develop, manufacture and commercialize the candidate for all potential indications. Teijin Pharma will receive an upfront cash payment of USD 30 million from Novartis and is eligible to receive potential development and commercial milestone payments of up to USD 200 million. Teijin Pharma is further eligible to receive additional sales milestones and tiered annual net sales royalties.
Read also: Novartis names Gilbert Ghostine as Chairman designate of Sandoz Board of Directors
